Objective: To evaluate the efficacy of bicalutamide vs cyproterone acetate in preventing PSA flare (as a surrogate for tumour flare) for patients requiring luteinizing hormone-releasing hormone (LHRH) analogue therapy for prostate cancer. Patients and Methods: In this pilot study, 40 men were randomized 1 : 1 to bicalutamide 50 mg o.d. or cyproterone acetate 100 mg t.i.d. 5 days prior to goserelin acetate and continued for 21 days thereafter. PSA, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and testosterone were obtained before treatment and on days 6, 8, 10, 16, 21 and 28. Primary end point was PSA. Hormone profile and clinical features including urinary symptoms and bone pain were secondary end points. Results: Both groups were equally matched apart from serum creatinine and ALP. The speed and magnitude of the percentage change in median PSA from baseline was increased for the CPA group but there was no statistically significant difference in the two groups. Although those receiving bicalutamide all showed a testosterone peak, this remained within the normal range. No difference in the frequency of drug-specific adverse events was found. None of the patients died or developed cord compression during the study period. Conclusion: Bicalutamide is able to suppress the initial PSA surge as effectively as cyproterone acetate albeit slightly delayed. A statement whether bicalutamide is equally good at preventing clinical flare cannot be made and should be assessed in an appropriately powered study. Prostate Cancer and Prostatic Diseases (2005) 8, 91-94.
Introduction
Despite a stage migration towards localized disease, many patients still present with locally advanced or metastatic prostate cancer. 1 The first-line treatment in this group is androgen deprivation therapy, usually with a luteinizing hormone-releasing hormone agonist (LHRHa). However, the initial surge in luteinizing hormone (LH) and hence testosterone prior to downregulation can cause disease flare in patients. Cyproterone acetate is the antiandrogen most often used to prevent flare. Bicalutamide is a newer nonsteroidal antiandrogen with a better side effect profile that is effective in treating prostate cancer and is also used by some clinicians to suppress flare.
We conducted a prospective randomized pilot study to assess whether bicalutamide is as effective as cyproterone acetate in preventing biochemical and clinical flare. Efficacy was assessed on the ability of bicalutamide to suppress PSA levels following administration of LHRHa.
Prevention of worsening bone-pain, LUTS, adverse events, serum LH and testosterone levels were secondary end points.
Patients and methods
In this pilot study, 40 patients from a single centre were randomized to receive either bicalutamide 50 mg o.d. or cyproterone acetate 100 mg t.i.d. 5 days prior to LHRHa therapy (a subcutaneous injection of goserelin acetate 3.6 mg). Both groups continued antiandrogen treatment for 21 days thereafter. Randomization was balanced by blocks of 4 and stratified by a computer-generated random-number table.
Eligible patients had histologically confirmed adenocarcinoma of the prostate stages T1c-T4, NX-N1, M0-M1 (TNM staging; UICC 2003). An isotope bone scan had been performed within 3 months of commencing treatment and all had a baseline PSA at least twice the age specific upper limit of normal and a serum testosterone level 45 nmol/l. Exclusion criteria were previous hormonal therapy for prostate cancer, other neoplastic lesion (apart from nonmelanomatous skin cancer), metastases of the central nervous system, renal (creatinineX2 Â normal) or liver (AST and ALTX3 Â normal) insufficiency, treatment with coumarin anticoagulants, corticosteroids, cimetidine or ketoconazole, hypophysectomy, adrenalectomy, use of any experimental drug within the last 3 months prior to the study, hypersensitivity to any of the study drugs, alcohol dependence, use of recreational drugs and inability to comply with the study protocol. All patients were counselled before the study and gave written informed consent. The protocol was approved by the hospital ethics committee.
Following randomization, patients and investigators were aware of which drugs were being used. At each visit, a full history and examination was undertaken including the IPSS and assesment of bone pain using a 100 mm visual analogue pain (VAP) score.
Serum levels of PSA, LH and testosterone were determined throughout the study on days 1 (visit1), 6, 8, 10, 16, 21 and 27 (final visit). In addition, blood samples for renal and liver function tests were measured. Safety assessments included targeted questioning and examination for potential adverse events as defined by the good clinical practice (GCP) guidelines. One investigator assessed the relationship between treatment and adverse events.
Group equivalence prior to treatment was assessed by the w 2 or Fisher's exact test for binary and categorical variables and by the Mann-Whitney U-test for nonparametric variables.
As the PSA values had a wide range of distribution, changes were graphically expressed as the percentage change of the median value between consecutive visits in the two groups. The Mann-Whitney U-test was used for statistical comparison of median PSA changes.
Changes in serum testosterone and LH levels were expressed as the median values on each evaluation day and compared between the groups using the MannWhitney U-test.
The bone pain scores were expressed as the number of men with an increase or decrease of more than 10 mm on the VAP score when compared to the value before LHRHa injection.
The frequency of adverse events was compared using the w 2 test. P-values less than 0.05 were considered significant.
Results
In all, 20 patients were randomized to each arm. None of the patients died during the study period. One patient on cyproterone acetate was withdrawn at the third visit due to new onset of dyspnoea and was subsequently admitted to hospital with a diagnosis of chest infection. All patients were followed up for a total of 27 days.
The summary statistics of the two groups is shown in Table 1 . All parameters were equally distributed between the two groups apart from the serum creatinine and ALP. Although more patients in the CPA group had metastasis this was not statistically significant ( Table 1) .
PSA and hormone profile
The median PSA before treatment was lower in the bicalutamide group, although this was not statistically significant. The magnitude and speed of the percentage of median PSA change was increased for the CPA group but there was no statistically significant difference between the groups, with no patient experiencing a rise in PSA between visits (Table 2 and Figure 1 ).
Changes in the LH level in the two groups were mirrored by the median testosterone levels ( Figure 2 , results for LH not shown). In the bicalutamide group, testosterone levels peaked on day 8 before falling steadily to reach castrate levels by day 27 (Figure 2) . In those on cyproterone acetate, there was an initial decrease in both hormone levels before a slight testosterone bounce on day 8 followed by a similar continuous decline (Figure 2 ). 
Adverse events
In total, three patients in the bicalutamide group experienced nonspecific adverse events compared to 11 on cyproterone acetate (Po0.001). None of the patients developed drug-specific adverse events such as renal or liver impairment based on biochemical parameters. Two patients in the cyproterone acetate group had serious nonspecific adverse events; one had worsening LUTS culminating in acute urinary retention which required admission and another had dyspnoea and chest infection as previously mentioned.
Discussion
Disease flare during initial LHRHa therapy can occur in 4-33% of patients 2 and may have a negative impact on quality of life. In this pilot study, we found that bicalutamide 50 mg o.d. was as effective as cyproterone acetate 100 mg t.i.d. in preventing a PSA surge (biochemical flare) as well as worsening symptoms (clinical flare), although a statement about the latter cannot be made safely from this study. Only an appropriately powered study will answer this question.
There has been no previous report on the role of bicalutamide specifically for the prevention of flare. In the context of combined androgen blockade (CAB) with an LHRHa, bicalutamide 50 mg od has been compared to flutamide 250 mg tds. 3 In the first report of the latter study, there was a similar incidence of flare 4 between the 2 groups.
Pharmacokinetic studies have also shown that bicalutamide 50 mg od is at least equivalent to flutamide 250 mg tds in terms of receptor affinity and potency. 5 The efficacy of flutamide in preventing flare has in turn been shown in several studies, although most of these were conducted in the context of CAB. [6] [7] [8] Its use is limited by gastrointestinal toxicity, haemolytic anaemia and visual disturbance.
Cyproterone acetate is a steroidal antiandrogen that acts on the pituitary as well as peripherally, and is thereby able to directly suppress LH production. 9 Side effects include direct hepatic toxicity, which may be fatal, increased risk of thromboembolism, sickle cell anaemia, depression and inhibition of spermatogenesis.
Bicalutamide is a newer nonsteroidal antiandrogen that is more peripherally selective. It has a good tolerability profile with demonstrated efficacy in various stages of prostate cancer. 10 In our study, there was no statistical difference in the percentage of median PSA decline in the two treatment arms. However, four patients on bicalutamide and three patients on CPA showed a slight PSA rise in the first week following LHRHa therapy; none of the patients Bicalutamide vs cyproterone acetate in preventing PSA M Sugiono et al experienced a sign of clinical flare. The magnitude and speed of PSA decline was increased for the CPA group. As expected, those on CPA showed an immediate decline in LH and testosterone levels. A small unexpected testosterone bounce was observed on day 8. In the bicalutamide group, there was an initial rise in LH and testosterone that peaked on day 8, caused by the selective blocking of peripheral androgen receptors. 11 The subsequent testosterone decline is solely ascribed to the LHRHa therapy. Nevertheless, in both arms, the median testosterone remained within the normal range (Figure 2) .
None of the patients developed cord compression during the study period.
There were significantly more patients experiencing nonspecific adverse events in the CPA group, most of whom had dyspnoea and fatigue which did not require any intervention. The one patient who developed acute retention underwent TURP. There were no drug-specific adverse effects in either group. Although nonspecific and drug-specific adverse effects can be difficult to disentangle. This is particularly true for symptoms such as dyspnoea which could theoretically be caused by fluid retention secondary to the progesterone-like characteristics of CPA.
The results indicate that bicalutamide 50 mg is able to prevent biochemical (PSA) flare as effectively as cyproterone acetate 100 mg t.i.d., possibly with fewer adverse effects. Although statistically insignificant, the speed and magnitude of PSA suppression was better for the CPA group. If one assumes that PSA is a surrogate for tumour flare 12 one may deduct from these results that bicalutamide also suppresses clinical tumour flare. However, this relationship is by no means well investigated. It therefore remains to be seen whether bicalutamide provides a useful and well-tolerated alternative in preventing flare during initial treatment with LHRHa.
On the basis of our results an appropriately powered study to assess the efficacy of bicalutamide vs cyproterone acetate for the prevention of tumour flare is possible. We do not believe the addition of a treatment arm with no antiandrogen for flare cover is ethically acceptable because even minimal metastatic burden at the wrong sites can sometimes lead to disastrous consequences. However, only the inclusion of a treatment arm with no flare cover would answer the questions about the clinical relevance of testosterone flare.
